Dr Adam Januszewski路 @AdamJanuszewski 路 X路路 1 day agoScore70
Body
馃毃 ?another practice-changing #ESMO2026 result!
Phase III #SAFFRON establishes osi + savo as a NEW SOC for EGFRm/MET+ #NSCLC progressing on osimertinib.
馃搱 PFS: 7.6 vs 5.4m (HR 0.55)
馃搱 significant OS: 17.8 vs 12.9m (HR 0.68)
馃敩 Importance of RE-BIOPSY at progression
11 views 路 0 likes 路 0 reposts 路 0 replies
Source: Dr Adam Januszewski 路 x.com